Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adver...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Scott, S A, Sangkuhl, K, Stein, C M, Hulot, J-S, Mega, J L, Roden, D M, Klein, T E, Sabatine, M S, Johnson, J A, Shuldiner, A R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2013
Soggetti:
CPIC Update
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748366/
https://ncbi.nlm.nih.gov/pubmed/23698643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2013.105
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi